Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

abstract：:It is apparent that treatment of Hodgkin's disease can be complicated by the development of secondary leukaemia. Most such leukaemias are of the non-lymphocytic type. We describe here a patient treated for Hodgkin's disease with chemo- and radiotherapy who developed secondary acute lymphoblastic leukaemia with a non-r...

journal_title：Leukemia

authors： Lennard A,Jackson GH,Carey PJ,Bown N,Middleton P,Proctor SJ

更新日期：1991-07-01 00:00:00

abstract：:The altered metabolism of cancer cells is a treasure trove to discover new antitumoral strategies. The gene (SLC7A5) encoding system L amino-acid transporter 1 (LAT1) is overexpressed in murine lymphoma cells generated via T-cell deletion of the pten tumor suppressor, and also in human T-cell acute lymphoblastic leuke...

journal_title：Leukemia

authors： Rosilio C,Nebout M,Imbert V,Griessinger E,Neffati Z,Benadiba J,Hagenbeek T,Spits H,Reverso J,Ambrosetti D,Michiels JF,Bailly-Maitre B,Endou H,Wempe MF,Peyron JF

更新日期：2015-06-01 00:00:00

abstract：:Leukemia-specific promoters and enhancers for gene therapy had never been reported. Since the Wilms' tumor gene WT1 is overexpressed in almost all types of leukemia, WT1 is an ideal target of leukemia-specific therapy. To explore the possibility of gene therapy for leukemia using WT1 promoter and enhancer, their activ...

journal_title：Leukemia

authors： Hosen N,Yanagihara M,Nakazawa T,Kanato K,Nishida S,Shirakata T,Asada M,Masuda T,Taniguchi Y,Kawakami M,Tsuboi A,Ikegame K,Oka Y,Ogawa H,Kawase I,Oji Y,Sugiyama H

更新日期：2004-03-01 00:00:00

abstract：:Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL tyrosine kinase domain (TKD) mutations are associated with acquired imatinib resistance, but their role in primary resistance is uncertain. Using highly sensitive ligat...

journal_title：Leukemia

authors： Pfeifer H,Lange T,Wystub S,Wassmann B,Maier J,Binckebanck A,Giagounidis A,Stelljes M,Schmalzing M,Dührsen U,Wunderle L,Serve H,Brück P,Schmidt A,Hoelzer D,Ottmann OG

更新日期：2012-07-01 00:00:00

abstract：:To determine the frequency and prognostic significance of recently described genetic lesions in pediatric acute lymphoblastic leukemia (ALL), all cases with available leukemic cell samples treated on St Jude Study XII were analyzed by molecular techniques for alterations of the p16, MLL and ETV6 genes. Homozygous p16 ...

journal_title：Leukemia

authors： Rubnitz JE,Behm FG,Pui CH,Evans WE,Relling MV,Raimondi SC,Harrison PL,Sandlund JT,Ribeiro RC,Grosveld G,Downing JR

更新日期：1997-08-01 00:00:00

abstract：:This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

journal_title：Leukemia

authors： Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

更新日期：2018-04-01 00:00:00

abstract：:The p53 tumor suppressor gene is frequently mutated within its evolutionarily conserved regions in a number of human cancers. Previous reports demonstrated mutations of this gene in both Burkitt's lymphoma and B cell chronic lymphocytic leukemia. However, dissimilar results were obtained in non-Hodgkin's lymphoma (NHL...

journal_title：Leukemia

authors： Li CC,O'Connell CD,Beckwith M,Longo DL

更新日期：1995-04-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a heterogeneous disease with multiple different cytogenetic and molecular aberrations contributing to leukemic transformation. We compared gene expression profiles of 4608 genes using cDNA-arrays from 20 AML patients (nine with -7/del7q and 11 with normal karyotype) with 23 CD34+ prepar...

journal_title：Leukemia

authors： Ritter M,Kattmann D,Teichler S,Hartmann O,Samuelsson MK,Burchert A,Bach JP,Kim TD,Berwanger B,Thiede C,Jäger R,Ehninger G,Schäfer H,Ueki N,Hayman MJ,Eilers M,Neubauer A

更新日期：2006-03-01 00:00:00

abstract：:Spliceosome mutations represent a new generation of acquired genetic alterations that affect both myeloid and lymphoid malignancies. A substantial proportion of patients with myelodysplastic syndromes (MDSs) or chronic lymphocytic leukemia (CLL) harbor such mutations, which are often missense in type. Genotype-phenoty...

journal_title：Leukemia

authors： Damm F,Nguyen-Khac F,Fontenay M,Bernard OA

更新日期：2012-09-01 00:00:00

abstract：:Myeloperoxidase (MPO) is found in the azurophilic granules of normal myelocytic cells. Cytochemical staining for MPO activity is used clinically to distinguish myeloid from acute lymphoid leukemias (ALL). However, using a highly sensitive RT-PCR technique, it is possible to detect MPO mRNA in otherwise clear ALL. The ...

journal_title：Leukemia

authors： Serrano J,Román J,Jiménez A,Castillejo JA,Navarro JA,Sánchez J,García-Castellanos JM,Martín C,Maldonado J,Torres A

更新日期：1999-02-01 00:00:00

abstract：:We have examined interactions between the purine nucleoside analog fludarabine (9-beta-arabinofuranosyl-2-fluoroadenine) and the macrocyclic lactone bryostatin 1 in the human monocytic leukemic cell line U937. Fludarabine exerted dose-dependent effects on U937 cell viability and growth which were associated with both ...

journal_title：Leukemia

authors： Vrana JA,Wang Z,Rao AS,Tang L,Chen JH,Kramer LB,Grant S

更新日期：1999-07-01 00:00:00

abstract：:LSD1 has emerged as a promising epigenetic target in the treatment of acute myeloid leukemia (AML). We used two murine AML models based on retroviral overexpression of Hoxa9/Meis1 (H9M) or MN1 to study LSD1 loss of function in AML. The conditional knockout of Lsd1 resulted in differentiation with both granulocytic and...

journal_title：Leukemia

authors： Barth J,Abou-El-Ardat K,Dalic D,Kurrle N,Maier AM,Mohr S,Schütte J,Vassen L,Greve G,Schulz-Fincke J,Schmitt M,Tosic M,Metzger E,Bug G,Khandanpour C,Wagner SA,Lübbert M,Jung M,Serve H,Schüle R,Berg T

更新日期：2019-06-01 00:00:00

abstract：:The presence of rare malignant stem cells supplying a hierarchy of malignant cells has recently been reported. In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction. To understand the origin of malignant cells in primary human B-pre...

journal_title：Leukemia

authors： Kong Y,Yoshida S,Saito Y,Doi T,Nagatoshi Y,Fukata M,Saito N,Yang SM,Iwamoto C,Okamura J,Liu KY,Huang XJ,Lu DP,Shultz LD,Harada M,Ishikawa F

更新日期：2008-06-01 00:00:00

abstract：:FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8+ and CD4+ T-cells expressing a FLT3-specific chimeric antigen receptor (CAR) and demonstrate they confer pot...

journal_title：Leukemia

authors： Jetani H,Garcia-Cadenas I,Nerreter T,Thomas S,Rydzek J,Meijide JB,Bonig H,Herr W,Sierra J,Einsele H,Hudecek M

更新日期：2018-05-01 00:00:00

abstract：:This phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit+ acute myeloid leukemia (AML). Imatinib was escalated through three dose levels in successive six patient cohorts. The combination was well t...

journal_title：Leukemia

authors： Brandwein JM,Hedley DW,Chow S,Schimmer AD,Yee KW,Schuh AC,Gupta V,Xu W,Kamel-Reid S,Minden MD

更新日期：2011-06-01 00:00:00

abstract：:Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during ...

journal_title：Leukemia

authors： Kayser S,Rahmé R,Martínez-Cuadrón D,Ghiaur G,Thomas X,Sobas M,Guerci-Bresler A,Garrido A,Pigneux A,Gil C,Raffoux E,Tormo M,Vey N,de la Serna J,Salamero O,Lengfelder E,Levis MJ,Fenaux P,Sanz MA,Platzbecker U,Schlen

更新日期：2020-09-01 00:00:00

abstract：:Signal transducer and activator of transcription (Stat)3 is constitutively activated in cutaneous T-cell lymphoma (CTCL), where it protects tumour cells against apoptosis. The constitutive activation of Stat3 leads to a constitutive expression of suppressor of cytokine signalling (SOCS)-3. In healthy cells, SOCS-3 is ...

journal_title：Leukemia

authors： Brender C,Lovato P,Sommer VH,Woetmann A,Mathiesen AM,Geisler C,Wasik M,Ødum N

更新日期：2005-02-01 00:00:00

abstract：:Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunological reactions, as they express no HLA class II and limited HLA class I ...

journal_title：Leukemia

authors： Balan A,Lucchini G,Schmidt S,Schneider A,Tramsen L,Kuçi S,Meisel R,Bader P,Lehrnbecher T

更新日期：2014-10-01 00:00:00

abstract：:Translocations involving the immunoglobulin loci are recurring events of B cell oncogenesis. The majority of translocations involve the immunoglobulin heavy chain (IGH) locus, while a minor part involves the immunoglobulin light chain loci consisting of the kappa light chain (IGK) located at 2p11.2 and the lambda ligh...

journal_title：Leukemia

authors： Poulsen TS,Silahtaroglu AN,Gisselø CG,Tommerup N,Johnsen HE

更新日期：2002-10-01 00:00:00

abstract：:Children with Down's syndrome (DS) have an increased risk of developing acute lymphoblastic leukemia (ALL) and have a low frequency of established genetic aberrations. We aimed to determine which genetic abnormalities are involved in DS ALL. We studied the frequency and prognostic value of deletions in B-cell developm...

journal_title：Leukemia

authors： Buitenkamp TD,Pieters R,Gallimore NE,van der Veer A,Meijerink JP,Beverloo HB,Zimmermann M,de Haas V,Richards SM,Vora AJ,Mitchell CD,Russell LJ,Schwab C,Harrison CJ,Moorman AV,van den Heuvel-Eibrink MM,den Boer ML,Zwaan

更新日期：2012-10-01 00:00:00

abstract：:Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is >80%. Outcome in adult ALL is still unsatisfactory, which is due to less cumulative dosing of chemotherapy and less strict adherence to timing of successive cycles. In the present phase II trial, we evaluated a pediatric regimen in...

journal_title：Leukemia

authors： Rijneveld AW,van der Holt B,Daenen SM,Biemond BJ,de Weerdt O,Muus P,Maertens J,Mattijssen V,Demuynck H,Legdeur MC,Wijermans PW,Wittebol S,Spoelstra FM,Dekker AW,Ossenkoppele GJ,Willemze R,Cornelissen JJ,Dutch-Belgian HO

更新日期：2011-11-01 00:00:00

abstract：:About half of the patients with follicular lymphoma will develop an aggressive B cell lymphoma with morphological changes in growth pattern and cellular morphology. Changes of the immunophenotype, especially of the expression of immunoglobulin (Ig) have been documented less frequently. Multiple tumor samples of two pa...

journal_title：Leukemia

authors： Raghoebier S,Broos L,Kramer MH,van Krieken JH,Kluin-Nelemans JC,van Ommen GJ,Kluin P

更新日期：1995-10-01 00:00:00

abstract：:We have analyzed the expression of Tdt and CD7 in 335 cases of unequivocal acute myeloid leukemia (AML). Tdt was expressed in 80 (25%) of 321 evaluable cases. Twenty-six of 77 (34%) Tdt+ patients assessable for response, entered complete remission (CR) vs 121 of 209 (58%) Tdt- cases (P < 0.001). CD7 was expressed in 1...

journal_title：Leukemia

authors： Venditti A,Del Poeta G,Buccisano F,Tamburini A,Cox-Froncillo MC,Aronica G,Bruno A,Del Moro B,Epiceno AM,Battaglia A,Forte L,Postorino M,Cordero V,Santinelli S,Amadori S

更新日期：1998-07-01 00:00:00

abstract：:In this study, we determined the respective roles of RelA and RelB NF-κB subunits in Epstein-Barr virus (EBV)-transformed B cells. Using different EBV-immortalized B-cell models, we showed that only RelA activation increased both survival and cell growth. RelB activity was induced secondarily to RelA activation and re...

journal_title：Leukemia

authors： Chanut A,Duguet F,Marfak A,David A,Petit B,Parrens M,Durand-Panteix S,Boulin-Deveza M,Gachard N,Youlyouz-Marfak I,Bordessoule D,Feuillard J,Faumont N

更新日期：2014-04-01 00:00:00

abstract：:Several tyrosine kinases such as Jak1, Jak3, Lck and Syk are known to participate in IL-2-mediated intracellular signal transduction. Jak1, Lck and Syk are associated with the cytoplasmic domain of the beta chain, whereas Jak3 is associated with the cytoplasmic domain of the gamma chain, which is shared among receptor...

journal_title：Leukemia

authors： Higuchi M,Asao H,Tanaka N,Oda K,Takeshita T,Sugamura K

更新日期：1997-04-01 00:00:00

abstract：:Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whe...

journal_title：Leukemia

authors： Griffiths SD,Cawley JC

更新日期：1988-06-01 00:00:00

abstract：:The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and aggressive lymphomas. Oral selective inhibitor of nuclear export (SINE) compou...

journal_title：Leukemia

authors： Hing ZA,Fung HY,Ranganathan P,Mitchell S,El-Gamal D,Woyach JA,Williams K,Goettl VM,Smith J,Yu X,Meng X,Sun Q,Cagatay T,Lehman AM,Lucas DM,Baloglu E,Shacham S,Kauffman MG,Byrd JC,Chook YM,Garzon R,Lapalombella R

更新日期：2016-12-01 00:00:00

abstract：:A prospective, randomized double-blind study comparing the effects of irradiated and unirradiated white blood cells was conducted in 108 acute leukemia patients with life-threatening infections, refractory to antibiotics. The study demonstrated no significant improvement in 30-day survival or overall survival. Transfu...

journal_title：Leukemia

authors： Freireich EJ,Lichtiger B,Mattiuzzi G,Martinez F,Reddy V,Kyle Wathen J

更新日期：2013-04-01 00:00:00

abstract：:Interleukin-2 (IL-2) is a growth factor which upon binding to high-affinity receptors (IL-2Ralphabetagamma) triggers mitogenesis in T cells. IL-2Ralpha expression is restricted to T cells which have recently encountered antigen, and in healthy individuals the majority (>95%) of peripheral T cells are IL-2Ralpha negati...

journal_title：Leukemia

authors： Eriksen KW,Kaltoft K,Mikkelsen G,Nielsen M,Zhang Q,Geisler C,Nissen MH,Röpke C,Wasik MA,Odum N

更新日期：2001-05-01 00:00:00

abstract：:The wt1 gene is located on chromosome 11p13 and encodes a zinc finger motif-containing transcription factor involved in regulation of growth and differentiation. Its expression was shown during embryonic development in various tissues as well as in a few human malignancies including acute leukemias. Using RT-PCR, we f...

journal_title：Leukemia

authors： Menssen HD,Renkl HJ,Rodeck U,Maurer J,Notter M,Schwartz S,Reinhardt R,Thiel E

更新日期：1995-06-01 00:00:00